Skip to content
Biodatica
Start free

Providence Health & Services

Portland, Oregon

OncologyantibodyPhase II
Compare Sign in to watch

What changed

Phase I trial registered: Ipilimumab for Head and Neck Cancer Patients

2mo agoTrial registeredApr 24, 2026Source filing (opens the source filing in a new tab)

Momentum

68no change

Momentum 68 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jun 17, 2025

    Advanced Solid Tumors · RECRUITING · sponsor: Providence Health & Services · A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

    ClinicalTrials.gov · NCT06719362 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Jan 15, 2018

    Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma · ACTIVE_NOT_RECRUITING · sponsor: Providence Health & Services · Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

    ClinicalTrials.gov · NCT03247712 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Nov 18, 2016

    Squamous Cell Carcinoma of the Head and Neck · ACTIVE_NOT_RECRUITING · sponsor: Providence Health & Services · Ipilimumab for Head and Neck Cancer Patients

    ClinicalTrials.gov · NCT02812524 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources